Phase 1 Study of Safety, Tolerability, PK, and PD of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with T2DM

被引：1
|
作者：
Ohwaki, Kenji
Furihata, Kenichi
Nasu, Risa
Oura, Tomonori
Imori, Makoto
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-742-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
742-P
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in individuals with type 2 diabetes by kidney function: ONWARDS 1-5
    Cheng, A. Y. Y.
    Rossing, P.
    Benamar, M.
    Laugesen, C.
    Nielsen, P. H.
    Bajaj, H. S.
    DIABETOLOGIA, 2024, 67 : S375 - S375
  • [22] Safety and tolerability of empagliflozin (EMPA) in phase III trials and their extensions in patients with type 2 diabetes (T2DM)
    Roden, M.
    Merker, L.
    Christiansen, A. V.
    Roux, F.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Lund, S. S.
    Hach, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S325 - S326
  • [23] Efficacy of once-weekly dulaglutide on HbA1c reduction in East Asian patients with T2DM: subgroup analysis according to potential influencing factors
    Peng, Yongde
    Zhang, Bin
    Hou, Jianing
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [24] Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Once-Weekly (OW) Semaglutide
    Frazer, Monica S.
    Swift, Caroline
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Alvarez, Sara B.
    Noone, Joshua
    Gamble, Cory L.
    DIABETES, 2022, 71
  • [25] Taspoglutide, a Once-Weekly Human GLP-1Analog, Improves Glucose Tolerance and Insulin Secretion in Patients with Type 2 Diabetes (T2DM): Results of a Meal Tolerance Test from T-emerge 2
    Rosenstock, Julio
    Balas, Bogdan
    Charbonnel, Bernard
    Bolli, Geremia B.
    Boldrin, Mark N.
    Ratner, Robert
    Balena, Raffaella
    DIABETES, 2010, 59 : A196 - A196
  • [26] Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes by Ethnicity and Race-ONWARDS 1-5
    Lingvay, Ildiko
    Bangsgaard, Katrine O.
    Desouza, Cyrus
    Marques, Mariana Fragao
    Navarria, Andrea, Sr.
    Vianna, Andre G.
    DIABETES, 2024, 73
  • [27] ASSESSMENT OF RACE-SPECIFIC TOLERABILITY AND EFFECTIVENESS OF EXENATIDE ONCE-WEEKLY OR BASAL INSULIN AMONG PATIENTS WITH TYPE 2 DIABETES IN A REAL WORLD SETTING IN THE USA
    Seeger, J. D.
    Nunes, A. P.
    Loughlin, A. M.
    Qiao, Q.
    Ezzy, S.
    Yochum, L. A.
    Clifford, C. R.
    Gately, R.
    Ohman, P.
    Dore, D. D.
    VALUE IN HEALTH, 2016, 19 (07) : A667 - A667
  • [28] A novel once weekly basal insulin Fc achieved similar glycaemic control with a comparable safety profile versus insulin degludec in patients with type 1 diabetes
    Kazda, C.
    Bue-Valleskey, J.
    Chien, J.
    Zhang, Q.
    Chigutsa, E.
    Landschulz, W.
    Wullenweber, P.
    Haupt, A.
    Dahl, D.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S329 - S329
  • [29] Glycaemic control with once weekly basal insulin Fc in persons with type 2 diabetes using continuous glucose monitoring in a phase 2 study
    Kazda, C.
    Chien, J.
    Zhang, Q.
    Chigutsa, E.
    Landschulz, W.
    Wullenweber, P.
    Haupt, A.
    Frias, J.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 113 - 113
  • [30] A Pragmatic Study of Basal and Mid-Mixture Insulins as Insulin Starters in Chinese Patients with T2DM
    Chen, Lulu
    Chen, Hong
    Du, Liying
    Lou, Ying
    Ji, Linong
    DIABETES, 2020, 69
12345